Free Trial

Bruce D. Analyst Performance

Analyst at Benchmark

Bruce D. is a stock analyst at Benchmark focused in the medical sector, covering 10 publicly traded companies. Over the past year, Bruce D. has issued 17 stock ratings, including buy and hold recommendations. While full access to Bruce D.'s proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Bruce D.'s coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
17 Last 0 Years
Buy Recommendations
94.12% 16 Buy Ratings
Companies Covered
10 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy94.1%16 ratings
Hold5.9%1 ratings
Sell0.0%0 ratings

Out of 17 total stock ratings issued by Bruce D. at Benchmark, the majority (94.1%) have been Buy recommendations, followed by 5.9% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
80.0% of companies on NASDAQ
8 companies
NYSE
20.0% of companies on NYSE
2 companies

Bruce D., an analyst at Benchmark, currently covers 10 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
9 companies
90.0%
Computer and Technology
1 company
10.0%

Bruce D. of Benchmark specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
50.0%
MED - DRUGS
2 companies
20.0%
MED PRODUCTS
1 company
10.0%
INSTRU - SCIENTFC
1 company
10.0%
SURGICAL APPLIANCES & SUPPLIES
1 company
10.0%

Bruce D.'s Ratings History at Benchmark

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4/17/2026Lower Price Target$95.08$120.00Buy
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
4/6/2026Lower Price Target$6.93$15.00Speculative Buy
Genelux Corporation stock logo
GNLX
Genelux
3/20/2026Lower Price Target$2.41$20.00Speculative Buy
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
3/13/2026Lower Price Target$4.94$6.00Speculative Buy
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
3/3/2026Reiterated Rating$176.17Buy
Humacyte, Inc. stock logo
HUMA
Humacyte
1/21/2026Lower Price Target$1.04$10.00Buy
Clene Inc. stock logo
CLNN
Clene
12/4/2025Reiterated Rating$6.68Buy
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
12/3/2025Reiterated Rating$153.69Buy
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
11/24/2025Downgrade$100.90Hold
Milestone Scientific Inc. stock logo
MLSS
Milestone Scientific
11/20/2025Lower Price Target$0.32$1.00Speculative Buy
Humacyte, Inc. stock logo
HUMA
Humacyte
11/13/2025Lower Price Target$1.19$11.00Buy
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
11/4/2025Boost Price Target$70.21$75.00Buy
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
10/31/2025Boost Price Target$98.93$132.00Buy
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
9/15/2025Lower Price Target$8.85$140.00Speculative Buy
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
9/15/2025Boost Price Target$3.87$21.00Speculative Buy
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
9/10/2025Lower Price Target$4.38$20.00Speculative Buy
Clene Inc. stock logo
CLNN
Clene
9/10/2025Lower Price Target$6.60$31.00Buy